AIVITA Biomedical Publishes Study Comparing Immune Responses and Associated Survivals Induced by Dendritic and Tumor Cell Vaccines – BioSpace
stemadminStem Cell MedicineNo comments

Findings confirmed that patient-specific autologous dendritic cell vaccines (DCV) induced a different immune response associated with longer survival than autologous tumor cell vaccines (TCV) IRVINE, Calif.--(BUSINESS WIRE)-- AIVITA Biomedical, Inc., a biotechnology company specializing in innovative cell therapy applications, announced today the publication of a paper titled, Cytokine network analysis of immune responses before and after autologous dendritic cell and tumor cell vaccine immunotherapies in a randomized trial, in the Journal of Translational Medicine. Robert O. Dillman, M.D., chief medical officer at AIVITA, and Gabriel I Nistor, M.D., chief scientific officer at AIVITA, authored the article

Read more
Incyte Announces Pivotal REACH2 Study Data Published in NEJM Highlight Superior Efficacy of Ruxolitinib (Jakafi) versus Best Available Therapy in…
stemadminStem Cell MedicineNo comments

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that data from the Phase 3 REACH2 study have been published in The New England Journal of Medicine demonstrating that ruxolitinib (Jakafi) improves outcomes across a range of efficacy measures in patients with steroid-refractory acute graft-versus-host disease (GVHD) compared to best available therapy (BAT). The results of REACH2, the first Phase 3 study of ruxolitinib in acute GVHD to have met its primary endpoint, reinforce findings from the previously-reported Phase 2 REACH1 study. In REACH2, patients treated with ruxolitinib experienced a significantly greater overall response rate (ORR) vs

Read more
Many cells in human uterus carry ‘cancer-driving’ mutations that arise early in life – News-Medical.Net
stemadminStem Cell MedicineNo comments

Many cells in the inner lining of the uterus carry 'cancer-driving' mutations that frequently arise early in life, report scientists from the Wellcome Sanger Institute, the University of Cambridge and their collaborators. The research team conducted whole-genome sequencing of healthy human endometrium, providing a comprehensive overview of the rates and patterns of DNA changes in this tissue. The work, published today (22 April 2020) in Nature, provides insights into the earliest stages of uterine cancer development.

Read more
Planned Clinical Trial of Allogeneic Stem Cell Therapy Remestemcel-L in Patients with COVID-19 – Cancer Network
stemadminStem Cell MedicineNo comments

Mount Sinai Health System announced that they will be using remestemcel-L (Ryoncil), an innovative allogeneic stem cell therapy, in patients with coronavirus disease 2019 (COVID-19). Additionally, Mount Sinai indicated that they will play a central role in a clinical trial for patients with severe acute respiratory distress syndrome, which affects individuals with severe cases of COVID-19. Remestemcel-L has previously been tested in patients who have had a bone marrow transplant, who can experience an overactive immune response similar to that observed in severe cases of COVID-19.

Read more
Northwestern Scientists Awarded Top Honors for Achievement in Clinical Research – Northwestern University NewsCenter
stemadminStem Cell MedicineNo comments

Northwestern University scientists received top honors from the Clinical Research Forum as part of its 2020 Top Ten Clinical Research Achievement Awards program, taking home the associations highest honor and capturing more finalist nominations than any other institution. The remarkable success of these brilliant and dedicated investigators shows the strength and breadth of Northwesterns clinical research program and demonstrates our shared commitment as an institution to groundbreaking science that transforms human health, said Eric G.

Read more

Theme: Illdy.